-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Viking Therapeutics, Lowers Price Target to $75

Benzinga·04/28/2025 13:50:36
Listen to the news
Truist Securities analyst Joon Lee reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $95 to $75.